Figure 3.

MDS-SCs engraft in humanized niches in NSG-SGM3 mice and demonstrate long-term self-renewal capacity. A, Representative flow cytometry plot showing the day 0 patient BM CD34/CD38 phenotype and engraftment of hCD45⁺ cells in humanized scaffolds as well as the hCD34/hCD38 phenotype of these xenografted cells in NSG-SGM3 mice. Pat ID, patient ID. B, Total hCD45⁺ cell engraftment in humanized scaffolds that were seeded with CD34⁺CD38⁻ MDS-SCs in NSG-SGM3 mice. C, Percentage of hCD45⁺ cells (left) in mice injected with CD34⁺CD38⁻ MDS cells and proportion of CD34⁺C38⁻/CD34⁺CD38⁺ cells within hCD34⁺ HSPCs in these humanized scaffolds retrieved from NSG-SGM3 mice. D, Percentage of hCD45⁺ cells and proportion of hCD34⁺ cells within the hCD45⁺ cell fraction in the humanized scaffolds that were seeded with MDS CD3⁻ MNCs. E, Schematic representation of the in vivo protocol for secondary transplantation. F, Percentage of total hCD45⁺ cells engrafted in humanized niches from primary and secondary NSG-SGM3 mice. G, Lineage distribution within the hCD45⁺ cells in humanized niches implanted in primary and secondary NSG-SGM3 mice. Mice were kept alive for up to 18 weeks following the scaffold implantation.